Related Experiment Video
Updated: Aug 7, 2026

Repeated Measurement of Respiratory Muscle Activity and Ventilation in Mouse Models of Neuromuscular Disease
Published on: April 17, 2017
Spinal muscular atrophy type 1: what are the ethics and practicality of respiratory support?
1University of Calgary, Alberta, Canada. ian.mitchell@calgaryhealthregion.ca
Insights
Spinal Muscular Atrophy Type I (SMA I), a severe infant condition, often leads to death by age two despite aggressive treatments. Pediatric respirologists must present all options, including palliative care, supporting family decisions.
Area of Science:
- Pediatric Neurology
- Neonatology
- Palliative Care
Background:
- Spinal Muscular Atrophy Type I (SMA I) is the most severe form of SMA, presenting in infancy.
- Without intervention, SMA I is typically fatal by two years of age.
- Current treatments focus on respiratory and nutritional support, but childhood mortality remains high.
Purpose of the Study:
- To emphasize the critical role of pediatric respirologists in discussing all treatment options for SMA I.
- To highlight the importance of supporting families in their decision-making process regarding infant care.
- To underscore the necessity of comprehensive, compassionate support throughout the disease trajectory.
Main Methods:
- This is a discussion-based abstract, not a research study.
- It outlines the clinical considerations and ethical responsibilities in managing SMA I.
- Focuses on communication strategies between healthcare providers and families.
Main Results:
- Aggressive treatments for SMA I do not guarantee survival beyond childhood.
- The decision-making process for families facing SMA I is inherently difficult.
- Palliative care is a crucial option that must be presented.
Conclusions:
- Pediatric respirologists must be adept at presenting all care options, including palliative care, for SMA I.
- Family autonomy and informed choice are paramount in managing SMA I.
- A multidisciplinary, compassionate team approach is essential from diagnosis through end-of-life care.
Abstract:
Spinal Muscular Atrophy Type I (SMA I) is the most severe form of SMA. It presents in infancy and without treatment death occurs by 2 years. Treatments in use address respiratory and nutritional issues but even with aggressive treatment death is still likely in childhood. Thus their use is not obligatory. However, pediatric respirologists must be willing and comfortable at presenting all treatment options, including the option of palliative care, to families and then supporting the family's choice. Whatever the chosen treatment regimen, decision making is difficult for families. Support and help must be provided from the time of presentation till death by a knowledgeable and compassionate team.
More Related Videos
04:16Inspiratory Muscle Training as an Adjunct to the Treatment of Weaning Failure in Critically Ill Patients: A Practical Guide
Published on: January 30, 2026
10:49Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation (NIPPV)
Cardiopulmonary Resuscitation II: ACLS Airway Management
Skeletal Muscle Relaxants: Therapeutic Uses
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Assessment of Airway, Skin Color, and Use of Accessory Muscles
Introduction
The initial evaluation of a patient's respiratory system...